Please assess the completion status of the following clinical trial:

Trial Title: Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer~* T1c-3 N0-2a~* Confirmed of hormonal receptor status~* HER2 positive confirmed by IHC 3+ or FISH+~* LVEF \> 50% by echocardiogram or MUGA~* Adequate EKG~* No prior treatment for breast cancer~* PS 0-1~* Required baseline laboratory data WBC \> 4,000/mm3 and Neut \> 2,000/mm3 PLT \> 100,000/mm3 Hb \> 9.0g/dl AST and ALT \< ULNx2.5 T-Bil \< 1.5mg/dl Serum creatinin \< 1.5mg/dl~* Written informed consent~Exclusion Criteria:~* With history of hypersensitivity reaction for important drug in this study~* With history of invasive breast cancer~* Bilateral invasive breast cancer~* Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus~* Positive for HBs antigen and with history of HVB~* With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension~* With severe edema~* With severe peripheral neuropathy~* With severe psychiatric disorder~* Pregnant or nursing women~* Cases who physician judged improper to entry this trial

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel (Type: EXPERIMENTAL): Nab-paclitaxel q3w 260mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).